Alzheimer's Disease Trial, Recruiting (NCT06923501)

Alzheimer's Disease Trial, Recruiting NCT06923501 Sponsor: Yale University Condition: Alzheimer's Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06923501 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Alzheimers Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are willing to follow all study procedures and are available for the full duration of the study, which includes 8 weeks of active participation and a 3-month follow-up period
People who have a confirmed cancer diagnosis, or who have been treated for cancer (including ongoing treatments after the main treatment) within the last two years
People who are over 18 years of age
People who can read and understand English
People who are able to use a mobile app with little to no help from the study team
People who are able to give their informed consent to participate

Who may not be able to join:

People who are currently receiving or plan to receive psychotherapy at any point during the study
People whose pre-study screening indicates an untreated or insufficiently treated mental health condition that may need referral to individual mental health care

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gabriel Cartagena, PhD, Yale University

Phone: 516-855-8539

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06923501

Sponsor: Yale University

Phase: Not Applicable

Status: Recruiting

Condition: Alzheimer's Disease

Trial contact: 516-855-8539

More information: https://clinicaltrials.gov/study/NCT06923501

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are willing to follow all study procedures and are available for the full duration of the study, which includes 8 weeks of active participation and a 3-month follow-up period
People who have a confirmed cancer diagnosis, or who have been treated for cancer (including ongoing treatments after the main treatment) within the last two years
People who are over 18 years of age
People who can read and understand English
People who are able to use a mobile app with little to no help from the study team
People who are able to give their informed consent to participate

Who may not be able to join:

People who are currently receiving or plan to receive psychotherapy at any point during the study
People whose pre-study screening indicates an untreated or insufficiently treated mental health condition that may need referral to individual mental health care

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Yale University

Registry

ClinicalTrials.gov

Start date

11 June 2026

Est. completion

1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Participant interest; Accrual; Participant completion; Participant satisfaction; Helpfulness; Acceptability; Usage

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov